KalVista Pharmaceuticals, Inc. (KALV)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch KALV
See up to 3 months of KALV. The 7-day demo opens the 1M and 3M ranges and puts KALV on your watchlist.
Start 7-day demoLatest KALV insider trades
Christopher Yea - OfficerOpen-market sale$905K- Christopher Yea - Officer
About KalVista Pharmaceuticals, Inc. (KALV)
The SEC lists KalVista Pharmaceuticals, Inc. under CIK 0001348911, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
KALV Form 4 activity by transaction type, last 90 days
No Form 4 activity for KALV in the last 90 days.
KALV insider transactions (Form 4)
12889 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nancy Stuart | Derivative | Stock Option (Right to Buy) | 14,000 | - footnote F3 | - | |
| Nancy Stuart | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Nancy Stuart | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Nancy Stuart | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Nancy Stuart | Derivative | Stock Option (Right to Buy) | 30,000 | - footnote F3 | - | |
| ||||||
 Brian Jg Pereira | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Brian Jg Pereira | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Brian Jg Pereira | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Brian Jg Pereira | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Brian Jg Pereira | Derivative | Stock Option (Right to Buy) | 30,000 | - footnote F3 | - | |
| Brian Jg Pereira | Derivative | Stock Option (Right to Buy) | 14,000 | - footnote F3 | - | |
| Brian Jg Pereira | Derivative | Stock Option (Right to Buy) | 7,000 | - footnote F3 | - | |
| ||||||
| William Fairey | Derivative | Stock Option (Right to Buy) | 17,000 | - footnote F3 | - | |
| William Fairey | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| William Fairey | Derivative | Stock Option (Right to Buy) | 30,000 | - footnote F3 | - | |
| ||||||
 Paul K. Audhya - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - footnote F3 | - | |
| Paul K. Audhya - Officer | Derivative | Stock Option (Right to Buy) | 25,800 | - footnote F3 | - | |
| Paul K. Audhya - Officer | Derivative | Restricted Stock Unit | 40,000 | - footnote F7 | - | |
| Paul K. Audhya - Officer | Derivative | Restricted Stock Unit | 68,750 | - footnote F7 | - | |
| Paul K. Audhya - Officer | Derivative | Restricted Stock Unit | 93,750 | - footnote F7 | - | |
| Paul K. Audhya - Officer | Derivative | Common Stock | 150,260 | $0.00 | - | |
| ||||||
 Bethany Sensenig | Derivative | Stock Option (Right to Buy) | 45,000 | - footnote F3 | - | |
| ||||||
| Patrick Treanor | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Patrick Treanor | Derivative | Stock Option (Right to Buy) | 30,000 | - footnote F3 | - | |
| Patrick Treanor | Derivative | Stock Option (Right to Buy) | 17,000 | - footnote F3 | - | |
| Patrick Treanor | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| ||||||
 Nicole Sweeny - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - footnote F3 | - | |
| Nicole Sweeny - Officer | Derivative | Restricted Stock Unit | 40,000 | - footnote F6 | - | |
| Nicole Sweeny - Officer | Derivative | Restricted Stock Unit | 68,750 | - footnote F6 | - | |
| Nicole Sweeny - Officer | Derivative | Restricted Stock Unit | 93,750 | - footnote F6 | - | |
| Nicole Sweeny - Officer | Derivative | Common Stock | 59,291 | $0.00 | - | |
| ||||||
| Bilal Arif - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - footnote F3 | - | |
| Bilal Arif - Officer | Derivative | Restricted Stock Unit | 49,000 | - footnote F6 | - | |
| ||||||
| Laurence Reid | Derivative | Stock Option (Right to Buy) | 17,000 | - footnote F3 | - | |
| ||||||
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 12,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 6,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 10,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 7,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 7,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 7,000 | - footnote F3 | - | |
| Edward W. Unkart | Derivative | Stock Option (Right to Buy) | 30,000 | - footnote F3 | - | |
| ||||||
 Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 33,750 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 75,000 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 85,000 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 37,500 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 20,000 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 25,800 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 40,000 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 113,920 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Restricted Stock Unit | 125,001 | - footnote F9 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Restricted Stock Unit | 255,750 | - footnote F9 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Restricted Stock Unit | 92,560 | - footnote F9 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Restricted Stock Unit | 304,688 | - footnote F9 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Common Stock | 479,989 | $0.00 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 47,354 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 29,611 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 33,800 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 71,700 | - footnote F3 | - | |
| Benjamin L. Palleiko - Officer | Derivative | Stock Option (Right to Buy) | 52,600 | - footnote F3 | - | |
| ||||||
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 53,500 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 52,600 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 27,900 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 60,000 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 31,000 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 20,000 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 18,920 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Stock Option (Right to Buy) | 80,000 | - footnote F3 | - | |
| Christopher Yea - Officer | Derivative | Restricted Stock Unit | 25,000 | - footnote F7 | - | |
| Christopher Yea - Officer | Derivative | Restricted Stock Unit | 41,250 | - footnote F7 | - | |
| Christopher Yea - Officer | Derivative | Common Stock | 229,918 | $0.00 | - | |
| ||||||
| Brian Piekos - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - footnote F3 | - | |
| Brian Piekos - Officer | Derivative | Restricted Stock Unit | 55,000 | - footnote F6 | - | |
| Brian Piekos - Officer | Derivative | Restricted Stock Unit | 93,750 | - footnote F6 | - | |
| Brian Piekos - Officer | Derivative | Common Stock | 21,661 | $0.00 | - | |
| ||||||
| Christopher Yea - Officer | Option exercise | Common Stock | 33,800 | $7.07 | $239K | |
| Christopher Yea - Officer | Open-market sale | Common Stock | 33,800 | $26.78 footnote F1 | $905K | |
| Christopher Yea - Officer | Option exercise | Employee Stock Option (Right to Buy) | 33,800 | $0.00 | - | |
| ||||||
| Christopher Yea - Officer | Option exercise | Common Stock | 3,125 | - footnote F1 | - | |
| Christopher Yea - Officer | Open-market sale | Common Stock | 1,966 | $26.78 | $53K | |
| Christopher Yea - Officer | Option exercise | Restricted Stock Unit | 3,125 | $0.00 | - | |
| ||||||
| Nicole Sweeny - Officer | Option exercise | Common Stock | 5,000 | - footnote F1 | - | |
| Nicole Sweeny - Officer | Open-market sale | Common Stock | 1,489 | $26.78 | $40K | |
| Nicole Sweeny - Officer | Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | |
| ||||||
| Paul K. Audhya - Officer | Option exercise | Common Stock | 5,000 | - footnote F1 | - | |
| Paul K. Audhya - Officer | Open-market sale | Common Stock | 2,239 | $26.78 | $60K | |
| Paul K. Audhya - Officer | Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | |
| ||||||
| Benjamin L. Palleiko - Officer | Option exercise | Common Stock | 23,250 | - footnote F1 | - | |
| Benjamin L. Palleiko - Officer | Open-market sale | Common Stock | 10,926 | $26.78 | $293K | |
| Benjamin L. Palleiko - Officer | Option exercise | Restricted Stock Unit | 23,250 | $0.00 | - | |
| ||||||
| Nicole Sweeny - Officer | Option exercise | Common Stock | 6,250 | - footnote F1 | - | |
| Nicole Sweeny - Officer | Open-market sale | Common Stock | 1,861 | $26.78 | $50K | |
| Nicole Sweeny - Officer | Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | |
| ||||||
| Christopher Yea - Officer | Option exercise | Common Stock | 3,750 | - footnote F1 | - | |
| Christopher Yea - Officer | Open-market sale | Common Stock | 2,358 | $26.78 | $63K | |
| Christopher Yea - Officer | Option exercise | Restricted Stock Unit | 3,750 | $0.00 | - | |
| ||||||
| Paul K. Audhya - Officer | Option exercise | Common Stock | 6,250 | - footnote F1 | - | |
| Paul K. Audhya - Officer | Open-market sale | Common Stock | 2,685 | $26.78 | $72K | |
| Paul K. Audhya - Officer | Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | |
| ||||||
| Brian Piekos - Officer | Option exercise | Common Stock | 5,000 | - footnote F1 | - | |
| Brian Piekos - Officer | Open-market sale | Common Stock | 1,489 | $26.78 | $40K | |
| Brian Piekos - Officer | Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | |
| ||||||
| Christopher Yea - Officer | Option exercise | Common Stock | 1,774 | - footnote F1 | - | |
| Christopher Yea - Officer | Open-market sale | Common Stock | 1,108 | $26.76 | $30K | |
| Christopher Yea - Officer | Option exercise | Restricted Stock Unit | 1,774 | $0.00 | - | |
| ||||||
| Paul K. Audhya - Officer | Option exercise | Common Stock | 2,419 | - footnote F1 | - | |
| Paul K. Audhya - Officer | Open-market sale | Common Stock | 1,032 | $26.76 | $28K | |
| Paul K. Audhya - Officer | Option exercise | Restricted Stock Unit | 2,419 | $0.00 | - | |
| ||||||
| Benjamin L. Palleiko - Officer | Option exercise | Common Stock | 2,419 | - footnote F1 | - | |
| Benjamin L. Palleiko - Officer | Open-market sale | Common Stock | 1,129 | $26.76 | $30K | |
| Benjamin L. Palleiko - Officer | Option exercise | Restricted Stock Unit | 2,419 | $0.00 | - | |
| ||||||
| Benjamin L. Palleiko - Officer | Option exercise | Common Stock | 7,120 | - footnote F1 | - | |
| Benjamin L. Palleiko - Officer | Open-market sale | Common Stock | 3,322 | $26.71 | $89K | |
| Benjamin L. Palleiko - Officer | Option exercise | Restricted Stock Unit | 7,120 | $0.00 | - | |
| ||||||
| Paul K. Audhya - Officer | Option exercise | Common Stock | 6,250 | - footnote F1 | - | |
| Paul K. Audhya - Officer | Open-market sale | Common Stock | 2,686 | $20.22 | $54K | |
| Paul K. Audhya - Officer | Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | |
| ||||||
| Nicole Sweeny - Officer | Option exercise | Common Stock | 6,250 | - footnote F1 | - | |
| Nicole Sweeny - Officer | Open-market sale | Common Stock | 1,862 | $20.22 | $38K | |
| Nicole Sweeny - Officer | Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | |
| ||||||
| Brian Piekos - Officer | Option exercise | Common Stock | 6,250 | - footnote F1 | - | |
| Brian Piekos - Officer | Open-market sale | Common Stock | 1,862 | $20.22 | $38K | |
| Brian Piekos - Officer | Option exercise | Restricted Stock Unit | 6,250 | $0.00 | - | |
| ||||||
| Benjamin L. Palleiko - Officer | Option exercise | Common Stock | 20,312 | - footnote F1 | - | |
| Benjamin L. Palleiko - Officer | Open-market sale | Common Stock | 9,550 | $20.22 | $193K | |
| Benjamin L. Palleiko - Officer | Option exercise | Restricted Stock Unit | 20,312 | $0.00 | - | |
| ||||||
Item 1.01, 1.02, 2.01, 2.03, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
Item 1.01, 7.01, 9.01
Item 2.02, 9.01
Recent KALV Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
KALV insider trading FAQ
What is the latest insider trade for KALV?
KalVista Pharmaceuticals, Inc. (KALV) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-11. The full record for KALV runs to 89 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying KALV stock?
No insider purchases of KALV were filed in the last 90 days.
How many insiders are selling KALV stock?
No insider sales of KALV were filed in the last 90 days. 60 sales are on record for this company.
Where can I see KALV SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects KALV Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Nancy Stuart view on EDGAR
- - Brian Jg Pereira view on EDGAR
- - William Fairey view on EDGAR
- - Paul K. Audhya view on EDGAR
- - Bethany Sensenig view on EDGAR
- - Patrick Treanor view on EDGAR
- - Nicole Sweeny view on EDGAR
- - Bilal Arif view on EDGAR
- - Laurence Reid view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where KALV's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow KALV with a 7-day demo
- KALV on your watchlist
- Every KALV Form 4 filing on record
- Up to 3 months of KALV price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
